NeuroQore is comprised of a team of passionate and motivated scientists, engineers, and clinicians dedicated to developing pioneering neuromodulation treatments for various neurobehavioral conditions. We collaborate with world-class universities and research clinics, in order to investigate ways to transform lives. At NeuroQore, we strive to create a world with effective solutions to devastating disorders: major depressive disorder and suicidality.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical / Health Care
- Market Focus:
- Globally (various continents)
Depression and Suicidality
Major depressive disorder affects approximately 16 million people in the U.S. and 121 million people worldwide, with a global economic burden of $2.5 trillion, annually. Even with the standard of treatment, which includes pharmaceuticals and concurrent cognitive behavioral therapy, 30%-40% will not respond to treatment, thereby classified as “treatment-resistant depression” (TRD). Despite the staggering prevalence of TRD and suicidality, there is limited knowledge of effective interventions within this population.
Current Standard: Inefficient and Outdated
Currently, an individual’s option for TRD and acute suicidality are repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT). ECT is the gold standard for these conditions, but while ECT can potentially be effective in treating TRD, and thereby suicidal ideation, its delayed onset of effect, which takes two to six weeks, limits its value in treating acutely suicidal patients. In addition, ECT is met with debilitating side effects and a strong element of social stigma for patients. A new treatment for TRD and acute suicidality is a critical priority. It is time that this gap in the healthcare system is addressed and new innovative approaches are investigated.